⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12320830 | 0.75 | RAB9A (0.33) | — | |
| SCHEMBL7005459 | 0.71 | — | — | |
| SCHEMBL3564666 | 0.69 | CCNB2 (0.31) | — | |
| SCHEMBL7010837 | 0.68 | AR (0.46) | — | |
| SCHEMBL7141497 | 0.68 | CA2 (0.41) | — | |
| SCHEMBL1680716 | 0.68 | MEN1 (0.31) | — | |
| SCHEMBL19066190 | 0.68 | HSP90AA1 (0.33) | — | |
| SCHEMBL21782492 | 0.67 | MEN1 (0.33) | — | |
| SCHEMBL972287 | 0.66 | AKR1C3 (0.33) | — | |
| SCHEMBL21330060 | 0.65 | CCNB2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2578590-B1 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KOREA INST SCI & TECH (KR) | 2017-08-16 | — | — | EP | disclosed |
| EP-2578590-B1 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KOREA INST SCI & TECH (KR) | 2017-08-16 | — | — | EP | disclosed |
| US-9062066-B2 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-06-23 | — | — | US | disclosed |
| US-9062066-B2 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-06-23 | — | — | US | disclosed |
| US-9062066-B2 | Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-06-23 | — | — | US | disclosed |
| EP-2578590-A2 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Korea Institute of Science and Technology (KR) | 2013-04-10 | — | — | EP | disclosed |
| US-20130072482-A1 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | PHAROSBIOMED CO., LTD. (KR) | 2013-03-21 | — | — | US | disclosed |
| US-20130072482-A1 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | PHAROSBIOMED CO., LTD. (KR) | 2013-03-21 | — | — | US | disclosed |
| US-20130072482-A1 | ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | PHAROSBIOMED CO., LTD. (KR) | 2013-03-21 | — | — | US | disclosed |
| EP-0690863-B1 | TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS | ABBOTT LAB (US) | 2003-03-05 | — | — | EP | disclosed |
| US-5597832-A | TREATMENT OF NEUROLOGICAL, PSYCHOLOGICAL, CARDIOVASCULAR DISORDERS, AND SUBSTANCE ABUSE, BEHAVIOR DISORDERS, COGNITIVE IMPAIRMENT AND ATTENTION DEFICIT DISORDER | ABBOTT LABORATORIES (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0690863-A1 | TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0690863-A4 | TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS | ABBOTT LAB (US) | 1995-11-07 | — | — | EP | disclosed |
| WO-1994022858-A1 | TETRACYCLIC COMPOUNDS AS DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1994-10-13 | — | — | WO | disclosed |